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C L I N I C A L R E S E A R C H A R T I C L E
Excess Mortality in Treated and Untreated
Hyperthyroidism Is Related to Cumulative
Periods of Low Serum TSH
Mads Lillevang-Johansen,1,2 Bo Abrahamsen,2,3,4 Henrik Løvendahl Jørgensen,5
Thomas Heiberg Brix,1 and Laszlo Hegedu¨s1
1Department of Endocrinology and Metabolism, Odense University Hospital, 5000 Odense, Denmark;
2Institute of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark; 3Odense Patient
Data Explorative Network OPEN, University of Southern Denmark, 5000 Odense, Denmark; 4Department
of Medicine, Holbæk Hospital, 4300 Holbæk, Denmark; and 5Department of Clinical Biochemistry,
Bispebjerg Hospital, 2400 Copenhagen, Denmark
Introduction and Aim: Cumulative time-dependent excess mortality in hyperthyroid patients has
been suggested. However, the effect of antithyroid treatment onmortality, especially in subclinical
hyperthyroidism, remains unclarified. We investigated the association between hyperthyroidism
and mortality in both treated and untreated hyperthyroid individuals.
Patients and Methods: Register-based cohort study of 235,547 individuals who had at least one
serum thyroid-stimulating hormone (TSH) measurement in the period 1995 to 2011 (7.3 years
median follow-up). Hyperthyroidism was defined as at least two measurements of low serum
TSH. Mortality rates for treated and untreated hyperthyroid subjects compared with euthyroid
controls were calculated using multivariate Cox regression analyses, controlling for age, sex, and
comorbidities. Cumulative periods of decreased serum TSH were analyzed as a time-dependent
covariate.
Results: Hazard ratio (HR) for mortality was increased in untreated [1.23; 95% confidence interval
(CI), 1.12 to 1.37; P , 0.001], but not in treated, hyperthyroid patients. When including cumulative
periods of TSH in the Cox regression analyses, HR for mortality per every 6 months of decreased TSH
was 1.11 (95% CI, 1.09 to 1.13; P , 0.0001) in untreated hyperthyroid patients (n = 1137) and 1.13
(95% CI, 1.11 to 1.15; P , 0.0001) in treated patients (n = 1656). This corresponds to a 184% and
239% increase inmortality after 5 years of decreased TSH in untreated and treated hyperthyroidism,
respectively.
Conclusions: Mortality is increased in hyperthyroidism. Cumulative periods of decreased TSH in-
creased mortality in both treated and untreated hyperthyroidism, implying that excess mortality
may not be driven by lack of therapy, but rather inability to keep patients euthyroid. Meticulous
follow-up during treatment to maintain biochemical euthyroidism may be warranted. (J Clin
Endocrinol Metab 102: 2301–2309, 2017)
Primary hyperthyroidism is a common conditionwith a prevalence of 0.8% to 1.3% and well-defined
regarding causes and treatment (1–3). It is biochemically
defined by a low concentration of serum thyroid-
stimulating hormone (TSH). Based on whether serum
levels of thyroxine (T4) and/or triiodothyronine (T3) are
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elevated or not, it can be subdivided into overt and
subclinical hyperthyroidism, respectively. Recent studies
have reported an association between hyperthyroidism
and increased risk of somatic comorbidities, such as
cardiovascular and pulmonary diseases (4, 5) and psy-
chiatric diseases (6). The burden of disease is increased
both prior to and after the diagnosis of hyperthyroidism
(5, 6). Large-scale register-based studies (4, 7) and sev-
eral meta-analyses (8–10) have supported an association
between hyperthyroidism and excess mortality. More-
over, our previous studies have indicated that duration of
suppressed TSH influence this increase in both mortality
and risk of major osteoporotic fractures (11, 12).
Although the available evidence points toward excess
mortality in hyperthyroidism, the studies are very in-
homogeneous in terms of study design, age and sex of the
subjects, use of confounder control, definition of hy-
perthyroidism, and exclusion of transient thyrotoxicosis.
Most importantly, none of these studies investigated
whether treatment of hyperthyroidism influenced mor-
tality risk. Previous studies (13–18) have found im-
provement of cardiovascular parameters after treatment
of hyperthyroidism (whether by antithyroid drugs, radio-
iodine, and/or surgery), but these studies are either
hampered by one or more shortcomings, such as lim-
ited study populations (N , 50) (13–16), inadequate
confounder control (13–18), or lack of mortality data
(13–16, 18). The results of the few studies which have
investigated mortality in treated hyperthyroid patients
show diverging results, with some showing increased
mortality (19, 20), and some not (21). As an example,
increased mortality in hyperthyroid patients treated with
radioactive iodine (RAI) doses insufficient to induce
hypothyroidism has been reported (19).
The current large-scale long-term cohort study aimed
at investigating the hitherto unclarified mortality risk in
both untreated and treated individuals with well-defined
hyperthyroidism. Additional focus was on the influence
of age, comorbidities, degree of hyperthyroidism, and
its duration.
Patients and Methods
Data sources
The Danish National Patient Register (DNPR) includes
admissions to Danish hospitals since 1 January 1977 and
outpatient visits since 1 January 1995 (22). All records are
based on the International Classification of Diseases (ICD)-8
and ICD-10 codes. The Department of Clinical Biochemistry
and Pharmacology at Odense University Hospital maintains
databases recording blood biochemistry ordered by hospitals
and practitioners, including all general physicians, on the Island
of Funen (population of 476,580 in January 2005). The Danish
National Prescription Register (DNPrR) contains data on all
medications dispensed by pharmacies in Denmark since 1995
(23). The Danish Register of Causes of Death contains data
regarding mortality (24). Crosslinking data between the reg-
isters is made possible through a unique 10-digit personal
identifier.
Study design and participants
This is an observational register-based cohort study in-
cluding all individuals on the Island of Funen with a TSH
measurement in the period 1 January 1995 to 1 January 2011.
The participants were followed from their first-ever TSH de-
termination until death or end of study (30 November 2012). In
this period, 275,467 individuals had at least one serum TSH
measurement. Danish health datasets become accessible to re-
searchers via Statistics Denmark only after a delay because of
the quality assurance and integrity checks undertaken by the
National Board of Health before database lock and release.
The inclusion process is described in additional detail in the
first analyses based on this dataset, published in 2014 (12).
Taking into account as exclusion criteria prior pituitary disease,
age ,18 years, prior treatment with antithyroid medication,
thyroid hormones, RAI or thyroid surgery, loss to follow-up and
emigration, and a 1-year washout period, 239,768 eligible
individuals with at least one TSH measurement remained.
In this study, thyroid function was defined from the first-ever
TSH determination. Hyperthyroidism was defined as having
a minimum of two decreased TSH values within a period of
6 months, with at least 14 days between measurements. This
was done to ensure the hyperthyroid status of the individuals,
and to reduce the likelihood of nonthyroidal illness or transient
thyrotoxicosis as the cause of lowTSH. Because of theminimum
of 14 days between TSH measurements, we left-truncated the
data and started follow-up 2 weeks after the first TSH mea-
surement. Individuals who either died or reached end of study
(30 November 2012) prior to the start of follow-up were ex-
cluded (n = 1807), as were individuals who were hypothyroid at
the first TSH determination, using the same criteria as for
hyperthyroid cases, albeit with an elevated TSH (n = 2414). This
left 235,547 participants, including 232,754 euthyroid con-
trols and 2793 hyperthyroid cases. Because being hyperthy-
roid (exposed) and euthyroid (unexposed) was defined by the
first-ever measured TSH and the nature of repeat blood mea-
surements, it was possible for controls to become hyper- and
hypothyroid during follow-up. During follow-up, 3687 un-
exposed controls became hyperthyroid, whereas 4119 became
hypothyroid. Because these individuals did not fulfill our initial
case definition, they were censored and exited the study at the
time of development of thyroid dysfunction.
Thyroid function
Euthyroidismwas defined as TSH between 0.3 and 4.0mIU/L,
and overt hyperthyroidism was defined as TSH ,0.3 mIU/L and
T4 .135.0 nmol/L and/or T3 .2.2 nmol/L. Subclinical hyper-
thyroidismwas characterized as TSH,0.3mIU/L andT4,135.0
nmol/L and T3 ,2.2 nmol/L. A TSH .4.0 mIU/L constituted
hypothyroidism.
Assays
All TSH determinations were done in the same laboratory.
In brief, until 2006, TSH was measured using a time-resolved
fluoroimmunoassay based on a direct sandwich technique
with three mouse antihuman monoclonal antibodies, and
2302 Lillevang-Johansen et al Mortality in Hyperthyroidism J Clin Endocrinol Metab, July 2017, 102(7):2301–2309
concentrations of T3 and T4 were analyzed using time-resolved
fluoroimmunoassays based on competitive binding to T3- or T4-
specific antibodies, respectively. Analyses were performed using
the AutoDELFIA equipment (Wallac, Turku, Finland). For TSH,
the limit of detection (LOD) was 0.005 mIU/L, whereas within-
run imprecision had a coefficient of variation (CV) of 2.7% at
0.89 mIU/L and 1.3% at 17.6 mIU/L. For T3 and T4, LOD was
0.3 and5.0 nmol/L, respectively, andCVwas 3.2%at 1.37 nmol/L
and 2.8% at 79.0 nmol/L, respectively.
From 2006, TSH was determined with a solid-phase, two-
site chemiluminescent immunometric assay on Immulite 2000
equipment (Siemens, Erlangen, Germany). The analytical LOD
was 0.004 mIU/L. Within-run CV was 5.3% at 0.32 mIU/L and
3.9% at 3.3 mIU/L. To assure compatibility between the two
analyses, method comparison was performed in 120 patient
samples showing comparable means (range, 0.008 to 49mIU/L)
and a regression coefficient of 0.991. Furthermore, an external
quality control program assured comparability (Ringversuche,
RfB, Bonn, Germany).
Treatment
Treatment was defined as having redeemed at least one
prescription of antithyroid drugs as registered in the DNPrR, or
having had thyroid surgery or RAI treatment as registered in the
DNPR, during follow-up. In the case of a participant having
received both antithyroid drugs and surgery/RAI, treatment
date was defined as whichever treatment was initiated first.
Outcome
The outcome was mortality. Data on time of death was
extracted from the Danish Register of Causes of Death.
Morbidity
The Charlson Comorbidity Index (CCI) is based on 19
disease groups (myocardial infarction, congestive heart failure,
peripheral vascular disease, cerebrovascular disease, dementia,
chronic pulmonary disease, rheumatic disease, ulcer disease,
diabetes mellitus with or without complications, hemiplegia,
moderate or severe renal disease, cancer with or without me-
tastases, leukemia, lymphoma, mild liver disease, moderate or
severe liver disease, and AIDS) (25). All disease categories were
identified from ICD-8 and ICD-10 codes in the DNPR (26). The
score reflects the time period from 1 January 1977 (estab-
lishment of DNPR) until the date of the first-ever TSH de-
termination, for both cases and controls.
Approvals
The project is approved by the Danish Data Protection
Agency and by Statistics Denmark to access health records.
Approval from the ethics committee was not needed. Odense
Patient data Explorative Network is an approved research in-
stitution permitted to access data hosted by Statistics Denmark
(project no. 704047).
Statistical analyses
Data processing was done in Stata V14.1 (StataCorp, Col-
lege Station, TX) and SAS version 9.4 (SAS Institute Inc., Cary,
NC) through virtual private network access to Statistics
Denmark.
Differences in baseline values of the outcome groups were
analyzed using nonparametric, parametric, or categorical
statistical methods where appropriate. Multivariate Cox pro-
portional hazards models were used to calculate hazard ratios
(HRs) for all-cause mortality in treated and untreated hyper-
thyroid individuals compared with controls. HRs were adjusted
for age, sex, and CCI. The validity of the proportional hazards
assumption was evaluated by inspection of Schoenfeld residuals
vs time, and Cox-Snell residuals. In large data sets one would
expect small deviations from the linear association between the
observed data points and the fitted value. No substantial de-
viations from the proportional hazards assumptions were
present.
Analyses using TSH level as a time-dependent covariate were
performed. Thus, the number of 6-month periods of decreased
TSH was incorporated as a cumulative covariate in the Cox
regression. This allowed analyzing the effect of decreased TSH
during follow-up rather than depending on the baseline clas-
sification alone, hence incorporating changes to thyroid status
over time rather than carrying the initial TSH value forward.
Any 6-month periods in which no further TSH measurement
had been performed were considered periods of normal TSH.
Sensitivity analyses were performed to analyze the influence
of immortal time bias regarding treatment, to adjust for possible
influence of postpartum thyroiditis and pregnancy on TSH
levels, and age stratification.
A significance level of 0.05 in two-tailed tests was used in
all analyses.
Results
We identified 2793 individuals who fulfilled our opera-
tional criteria for hyperthyroidism, 486 of whom only
had data on TSH. There were 232,754 individuals with at
least one TSHmeasurement within the normal rangewho
constituted the control group. There were 1656 (59.3%)
hyperthyroid individuals who received treatment during
follow-up, whereas 1137 (40.7%) did not (Fig. 1).
Subdivision by degree of hyperthyroidism identified
1909 individuals with overt hyperthyroidism and 498with
subclinical hyperthyroidism. There were 1309 (68.6%)
overtly hyperthyroid individuals and 140 (28.1%) sub-
clinically hyperthyroid individuals who subsequently re-
ceived treatment during follow-up.
Baseline characteristics are summarized in Table 1.
The control group was significantly younger and con-
tained fewer women than the hyperthyroid groups. The
controls had a significantly lower burden of comorbidity
than the untreated hyperthyroid individuals, but not
compared with the treated ones. Median follow-up time
was nominally shorter in the control group compared
with all the hyperthyroid groups, with exception of the
untreated subclinically hyperthyroid individuals. Median
follow-up in the entire study population was 7.3 years
(range, 0 to 16.9 years).
At baseline, overtly hyperthyroid individuals who
subsequently received treatment during follow-up had
significantly higher levels of T4 and T3 than the untreated
individuals (P , 0.0001). Significantly higher baseline
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levels of T3 were observed in the treated subclinically
hyperthyroid individuals than in the untreated individuals
(P = 0.0071) (Table 2).
Mortality in the entire hyperthyroid group
During a median follow-up of 9.4 years (range, 0 to
16.9 years), 476 treated individuals died (28.7%), which
was significantly fewer than in the untreated group
where, during a median follow-up time of 7.8 years
(range, 0 to 16.7), 389 died (34.2%) (P, 0.005). TheHR
for all-cause mortality in the treated hyperthyroid in-
dividuals was 1.49 [95% confidence interval (CI), 1.36 to
1.73; P , 0.001], and 2.06 (95% CI, 1.86 to 2.28; P ,
0.001) in the untreated hyperthyroid individuals. When
adjusting for age, sex, and comorbidities, the HR in the
treated group was 1.01 (95% CI, 0.92 to 1.10; P value is
not significant), but still significantly increased in the
untreated group (HR, 1.24; 95% CI, 1.12 to 1.37; P ,
0.001) (Table 3). Due to power reasons, we did not find
it meaningful to evaluate the effect of different treatment
modalities because only 173 treated hyperthyroid pa-
tients received either RAI or surgery at some point during
follow-up, and only 68 of these were first-line treatments.
Mortality in overt hyperthyroidism
When compared with the control population, mor-
tality was significantly increased in both treated and
untreated overtly hyperthyroid individuals (HR, 1.36;
95% CI, 1.22 to 1.51; P, 0.001 and HR, 1.49; 95% CI,
1.27 to 1.74; P , 0.001, respectively). Irrespective of
Figure 1. Flowchart describing the inclusion process.
Table 1. Baseline Characteristics of the Study Population According to Thyroid Status, Treatment, and
Number of Deaths
Characteristic
Entire Hyperthyroid Group
Subclinical
Hyperthyroidism Overt Hyperthyroidism
Controls
(n = 232,754)
Treatment
(n = 1656)
No Treatment
(n = 1137)
Treatment
(n = 140)
No Treatment
(n = 358)
Treatment
(n = 1309)
No Treatment
(n = 600)
Age at first
TSH6 standard
deviation
59.9 6 17.7a 62.5 6 16.8a,b 65.9615.8a 66.4 6 15.7a 58.4 6 17.7a 59.6 6 16.9a 51.0 6 18.2
Females (%) 81.2a 72.8a,b 75.0a 69.6a 81.4a 74.0a,b 55.8
CCI (%) 0 79.1 70.8a,b 70.7 67.0a 80.8 74.8a,b 79.6
1 13.9 18.8a,b 18.6 20.7a 12.8 16.7a,b 13.9
2 4.4 6.0a,b 5.7 7.8a 4.3 4.8a,b 3.6
$3 2.6 4.4a,b 5.0 4.5a 2.1 3.7a,b 2.9
Median follow-up
years (range)
9.4 (0–16.9)a 7.8 (0–16.7)a,b 8.6
(0.2–16.8)a
7.3 (0.1–16.5)b 9.2 (0–16.9)a 8.1 (0.1–16.7)a 7.2 (0–16.9)
Deaths, n (%) 476 (28.7)a 389 (34.2)a,b 50 (35.7)a 151 (42.2)a 337 (25.7)a 152 (25.3)a 36,487 (15.7)
aSignificantly different compared with controls.
bSignificantly different than treated within the same group.
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treatment status, this excess mortality attenuated andwas
no longer significantly increased when adjusting for age,
sex, and comorbidities (Table 3).
Mortality in subclinical hyperthyroidism
Subclinically hyperthyroid individuals who received
treatment had significantly increasedmortality compared
with euthyroid controls (HR, 1.95; 95%CI, 1.48 to 2.58;
P , 0.001). This was also the case for the untreated
individuals (HR, 2.70; 95%CI, 2.30 to 3.17; P, 0.001).
When adjusted for age, sex, and comorbidities, the
mortality in the treated group was not significantly dif-
ferent from that in the control population, whereas the
HR for mortality in the untreated individuals attenuated,
but remained significantly higher than in the controls
(HR, 1.36; 95% CI, 1.16 to 1.60; P , 0.001) (Table 3).
Mortality and cumulative exposure to low TSH
In untreated hyperthyroid individuals, the HR for
mortality per every 6 months of decreased TSH was 1.11
(95% CI, 1.09 to 1.13; P , 0.0001). In the treated hy-
perthyroid individuals, the HR for mortality per every
6 months of decreased TSH was 1.13 (95% CI, 1.11 to
1.15; P , 0.0001). This corresponds to a 184% and
239% increase in mortality, respectively, after 5 years of
low TSH. When subdividing into degree of hyperthy-
roidism, the HR for mortality per every 6 months of
decreased TSH was 1.16 (95% CI, 1.13 to 1.18; P ,
0.0001) in the untreated overtly hyperthyroid individuals
and 1.14 (95% CI, 1.12 to 1.17; P , 0.0001) in treated
individuals. In the untreated subclinically hyperthyroid
individuals, the HR for mortality per every 6 months of
decreased TSH was 1.15 (95% CI, 1.12 to 1.18; P ,
0.0001) and 1.18 (95% CI, 1.16 to 1.21; P, 0.0001) in
treated subjects. Only 73 individuals received T4 re-
placement after RAI or surgery, which did not allow for
any meaningful statistical evaluation of excess treatment
on mortality.
Sensitivity analyses
Excluding hyperthyroid patients who were registered
with a diagnosis of postpartum thyroiditis or had contact
to hospitals regarding pregnancy in a 9-month period
before and after first-evermeasured TSH did not alter our
findings. We also stratified age into ,65 and $65 years.
In this analysis, mortality was increased in the entire
group of untreated hyperthyroid individuals $65 years,
and in the untreated subclinically hyperthyroid in-
dividuals $65 years, but not those below (data not
shown).
Because 292 of the 1656 treated hyperthyroid in-
dividuals (17.6%) did not start treatment within the first
year of becoming hyperthyroid, there was a risk of intro-
ducing immortal time bias, also known as guarantee-time
Table 3. Mortality in Individuals With Hyperthyroidism Compared With Controls
Entire Hyperthyroid Group
(n = 2793)
Subclinical Hyperthyroidism
(n = 498)
Overt Hyperthyroidism
(n = 1909)
Treated vs
Controls
Untreated vs
Controls
Treated vs
Controls
Untreated vs
Controls
Treated vs
Controls
Untreated vs
Controls
Unadjusted HR 1.49 (1.36–1.63)a 2.06 (1.86–2.28)a 1.95 (1.48–2.58)a 2.70 (2.30–3.17)a 1.36 (1.22–1.51)a 1.49 (1.27–1.74)a
Adjusted HRb 1.01 (0.92–1.10) 1.24 (1.12–1.37)a 0.87 (0.66–1.15) 1.36 (1.16–1.60)a 1.03 (0.93–1.15) 1.03 (0.88–1.20)
Values are expressed as HR (95% CI).
aP , 0.001.
bAdjusted for age, sex, and CCI.
Table 2. Baseline Serum T4 and T3 Levels at Inclusion in Subsequently Treated and Untreated Hyperthyroid
Individuals
Subclinical Hyperthyroidism Overt Hyperthyroidism
Treatment No Treatment Treatment No Treatment
n 140 358 995 526
T3 (nmol/L) 1.87 6 0.28 1.79 6 0.30a 4.05 6 2.45 2.61 6 0.70b
n 140 358 1306 599
T4 (nmol/L) 110.8 6 16.6 108.2 6 17.6 193.7 6 61.4 147.2 6 33.2b
Data are presented as mean 6 standard deviation or as otherwise indicated. Data are compared within group.
aP = 0.0071.
bP , 0.0001.
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bias (27). This bias arises when allocation into a certain
study group is defined by an incident during follow-up,
in this case, treatment. As an example, a hyperthyroid
patient who starts treatment at some point during follow-
up is effectively immortal until this point in time. This
may lead to an overestimation of survival in this group.
We performed a sensitivity analysis where follow-up
started 1 year after the date of the first TSH measure-
ment; therefore, hyperthyroid individuals who started
treatment after this date were classified as untreated for
the remainder of the follow-up (28). This did not affect
our results significantly (Table 4).
Discussion
Using a large-scale, register-based, long-term cohort
study of biochemically verified treated and untreated
hyperthyroid individuals, we demonstrate excess mor-
tality in the individuals who did not receive antithyroid
treatment, as compared with euthyroid controls. One
of the major strengths in our study lies in the utiliza-
tion of two TSH measurements when defining hyper-
thyroidism. Previous studies also reported increased
mortality in hyperthyroid patients, but relied on either
diagnosis codes (7) or only a single measurement of
TSH (4, 11). Clearly, a case definition based on a single
TSH measurement is hampered by a high risk of mis-
classification of hyperthyroidism because of transient
thyrotoxicosis. In fact, approximately 50% of patients
with a decreased TSH will have normal levels at repeat
investigation (29). If only using one TSH measure-
ment in this cohort, 6424 individuals would have been
included in the case group rather than the control
group, highlighting the pitfalls regarding case defini-
tion. Using a single measurement of TSH as a case def-
inition also carries a risk of introducing selection bias.
Thus, the fact that a person admitted to hospital, who
happens to have a low TSH measurement, may die
immediately after because of reasons unrelated to
hyperthyroidism, introduces higher mortality in this
group. By requiring two TSH values, we reduced the
risk of this bias.
The major novelty of our study lies in the evaluation
of untreated and treated hyperthyroid patients. The
hyperthyroid individuals receiving treatment had mor-
tality similar to that of the controls, whereas those left
untreated had an increased mortality. Although some
previous studies found increased mortality in treated
hyperthyroid individuals (19, 20), others did not (21,
30). Interestingly, and in line with our results, Boelaert
et al. (19) found that patients who developed hypo-
thyroidism after RAI treatment had mortality similar
to that of the background population. However, the
aforementioned studies are very inconsistent in con-
trolling for comorbidities, which constitutes a challenge
in interpretation of the results because the burden of
comorbidities influences mortality (7). The CCI, as used
in this paper, is a highly valid method for controlling for
comorbidities known to impact strongly on mortality,
allowing examination of a direct association between
hyperthyroidism and mortality. With this approach,
the mortality risk in treated hyperthyroid individuals
was attenuated when controlling for comorbidities,
stressing the paramount importance of confounder
control. Importantly, and a limitation, previous studies
examining the effect of antithyroid treatment in hy-
perthyroid subjects only investigated patients with
overt hyperthyroidism. In our study, we subdivided
according to severity of thyroid dysfunction, and
demonstrate that treated patients with subclinical
hyperthyroidism have a mortality risk similar to the
euthyroid controls, whereas mortality is increased in
the untreated. A number of previous studies have
shown increased mortality in subclinically hyperthyroid
Table 4. Sensitivity Analysis—Mortality
Entire Hyperthyroid Group
(n = 2665)
Subclinical Hyperthyroidism
(n = 464)
Overt Hyperthyroidism
(n = 1849)
Treated vs
Controls
Untreated vs
Controls
Treated vs
Controls
Untreated vs
Controls
Treated vs
Controls
Untreated vs
Controls
Unadjusted HR 1.44 (1.29–1.61)a 2.02 (1.84–2.23)a 1.71 (1.48–2.58)b 2.62 (2.23–3.07)a 1.33 (1.17–1.51)a 1.64 (1.42–1.89)a
Adjusted HRc 1.10 (0.99–1.23) 1.12 (1.02–1.23)b 0.90 (0.57–1.43) 1.27 (1.08–1.50)d 1.10 (0.97–1.25) 1.02 (0.88–1.18)
Values are expressed as HR (95% CI). Follow-up started 1 year after the date of the first TSH measurement, implying that hyperthyroid individuals who
started treatment after this date were classified as untreated for the remainder of the follow-up. There were 8373 subjects who exited the study or died
before the start of follow-up, and 292 subsequently treated hyperthyroid individuals were regarded as untreated.
aP , 0.001.
bP = 0.022.
cAdjusted for age, sex, and CCI.
dP = 0.003.
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individuals (4, 9, 11, 31, 32), but only one study had
information regarding treatment (4). However, that
study did not differentiate between treated and un-
treated individuals.
Accepting that there seems to be increasedmortality and
increased risk of cardiovascular events in subclinically
hyperthyroid patients, disagreement on whether such pa-
tients should receive antithyroid treatment persists (33, 34).
In the 2015 guidelines of the European Thyroid Associa-
tion, treatment of patients .65 years of age with grade 2
(TSH ,0.1 mIU/L) subclinical hyperthyroidism is recom-
mended, whereas the recommendation for patients ,65
years is weak with low-quality evidence (35). When strat-
ifying by age, we showed an increased mortality in un-
treated subclinically hyperthyroid patients above but not
below 65 years. It is important to accept that the latter
finding may rely on lack of power because only 155 pa-
tients with subclinical hyperthyroidism age,65 years did
not receive treatment. Although earlier attempts have been
unsuccessful, the current findings reinforce the need for
randomized interventional studies in this condition.
At variance with a number of recent studies showing
an increase in mortality among hyperthyroid individuals
(4, 7, 11), we found no excess mortality in the overtly
hyperthyroid group, whether treated or not. One possible
explanation for the diverging results is that wemay in fact
be underestimating the effect of hyperthyroidism, and
that of treatment, on mortality. As evident from our
baseline characteristics, the treated overtly hyperthyroid
individuals had significantly more pronounced thyroid
dysfunction than the untreated. Thus, a potential increase
in mortality may have been offset because of treatment.
The consensus is to treat overt hyperthyroidism, and why
treatment was withheld or declined in the untreated in-
dividuals remains unanswered. This hardly indicates
possible errors in the database system for recording
treatment because the DNPrR is a highly valid national
database that electronically records any prescription
dispensed to any individual in any pharmacy. A study
investigating primary nonadherence with prescribed
medication has shown that 31.3% of incident prescrip-
tions are not redeemed, which could help explain
why .30% of overtly hyperthyroid patients do not re-
ceive treatment (36). Another possibility could be that a
patient dies or reaches the end of study before being able
to initiate treatment. This scenario seems implausible
when taking into account the results of our sensitivity
analysis where we essentially find similar results. More
likely, these untreated patients may have mild and oli-
gosymptomatic disease, possibly with spontaneous re-
mission (37), or may be among the 7% of hyperthyroid
cases caused by reversible causes, such as subacute thy-
roiditis, and treatment with amiodarone or lithium (2).
These are factors that may explain the lack of excess
mortality in this group. It is also important to emphasize
that these results are based on the first thyroid function
tests and do not take into account changing thyroid
status. Our cumulated dose-dependent mortality analy-
sis, adjusted for age, sex, and comorbidities, demon-
strated an 11% and 13% increase in mortality per
6 months of decreased TSH in untreated and treated
hyperthyroid patients, respectively. This corresponds to a
184% and 239% increase in mortality after 5 years of
decreased TSH, respectively, in the two groups. Essen-
tially similar results were found when subdividing into
overt and subclinical hyperthyroidism. Our findings in
the multivariate Cox regression together with the results
from the cumulative analysis indicate a beneficial effect of
treatment of hyperthyroidism with lowering of excess
mortality. Close monitoring of therapy and maintaining
euthyroidism may be equally important.
We lack information on clinical covariates such as
smoking status and alcohol consumption, both of which
influence the risk of hyperthyroidism and mortality (38,
39). However, adjusting for a number of somatic dis-
orders, including chronic pulmonary disease, cancer, and
liver disease, disorders very firmly linked to smoking and
alcohol consumption and mortality, our findings are at
least in part adjusted for the possible effect of smoking
and alcohol. We had no information on the clinicians’
decision of either initiating or withholding treatment,
neither do we know the reason for TSH being measured
in the first place. The TSH determination presumably has
been performed because of suspicion of thyroid disease,
or in the context of general testing, and it is important
to emphasize that the control population is not a ran-
dom population sample, and thus does not necessarily
represent a healthy background population. Therefore,
even when controlling for comorbidities, we may have
underestimated the mortality displayed in our analyses.
There are two inherent limitations in investigating
TSH as a time-varying covariate. First, we classified any
6-month period with no TSH measurement as a euthy-
roid period. This implies that a study participant may de
facto remain hyperthyroid, although considered euthy-
roid in the analysis. Hypothetically, this would lead to an
underestimation of the effect of hyperthyroidism and
lowering of the risk estimate of mortality because actual
hyperthyroid individuals remain part of the control
group. The register-based approach does not allow us to
quantify this. Second, shorter survival irrespective of
cause will reduce the number of 6-month periods in
which a patient could be flagged as biochemically hy-
perthyroid. This would conservatively bias our risk es-
timates in the cumulative analysis rather than inflate the
importance of achieving euthyroidism. Neither were we
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able to differentiate between the two major causes of
hyperthyroidism: Graves disease and toxic nodular goi-
ter. Theoretically, because of differences in age distri-
bution, burden of comorbidity, and cause of death between
the two phenotypes, treatment effect onmortality may also
differ (2, 40). Because of the nature of our data,wewere not
able to distinguish between the two. Ideally, treatment
should be analyzed as a time-varying covariate to reduce
the risk of immortal time bias, considering that treated
hyperthyroid individuals are by design immortal in the
period from first TSH determination until start of treat-
ment. In our study cohort, 292 patients did not start
treatment until$1 year after the first measured TSH value.
In viewof the first TSH in these cases logically not being the
deciding factor for treatment initiation, we found it ac-
ceptable to consider these patients as untreated in the
sensitivity analysis, to reduce the risk of bias. This method
did not change our results significantly, indicating that this
bias is of little importance.
In conclusion, cumulative periods of decreased TSH
increased mortality in both treated and untreated hy-
perthyroidism. This suggests that excess mortality may
not be driven by lack of therapy, but rather inability to
keep patients euthyroid. Meticulous follow-up during
treatment to maintain biochemical euthyroidism may be
warranted. Qualifying these statements further will need
carrying out of prospective randomized interventional
studies, especially in subclinical hyperthyroidism.
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